Table 2. Characteristics of Patients in Endovascular and Medical Treatment Arms.
| Author | Characteristics of patients in endovascular arm | Characteristics of patients in medical arm | ASPECTS dichotomy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients | High:Low ASPECTS | male, n | Age, mean (SD), y | ASPECT, median (IQR) | NIHSS, median (IQR) | No. of patients | High:Low ASPECTS | male, n | Age, mean (SD), y | ASPECT, median (IQR) | NIHSS, median (IQR) | ||
| Hill18 (PROACT-III) | 105 | 46: 59 | NA | NA | NA | NA | 49 | 20:29 | NA | NA | NA | NA | 0–7, 8–10 |
| Imai19 | 90 | 58 | 73 (10.5) | NA | 18 (7–26)h | MRI-ASPECTS (5–7, 8–10) | |||||||
| Psychogiosa 20 | 48 | 28 | 69 (21–86)g | 8 (6.5–9) | 17.5 (6)h | 0–7, 8–10 | |||||||
| Hill21 (IMS-III) | 434 | 247:187 | 218 | 69 (23–89)g | NA | 17 (7–40) | 222 | 131:91 | 122 | 68g | NA | 16 | 0–7, 8–10 |
| Inoue22 | 210 | 94 | 70.4 (16.8) | 6 (4–8) | 16 (11–21) | MRI-ASPECTS (0–7, 8–10) | |||||||
| Yoo11 | 249 | 124 | 66.6 (15.0) | 8 (6–9) | 17 (13–21) | 0–7, 8–10 | |||||||
| Espinosa de Rueda12 | 150 | 77 | 66.3 (12.6) | 8 (7–9) | 17 (13–22) | 3–7, 8–10 | |||||||
| Goyal3 (ESCAPE)c | 153 | 128:25 | 79 | 71 (60–81)i | 9 (8–10) | 16 (13–20) | 151 | 122:29 | 71 | 70 (60-81)i | 9 (8–10) | 17 (12–20) | 0–7, 8–10j |
| Jovind 4 | 103 | 50:53 | 55 | 65.7 (11.3) | 7 (6–9) | 17 (14–20) | 103 | 55:48 | 54 | 67.2 (9.5) | 8 (6–9) | 17 (12–19) | 6–7, 8–10 |
| McTaggart23 (DEFUSE-II)e | 74 | NA | 67 (15) | 7.6h | 17 (12–20) | 0–7, 8–10 | |||||||
| Saver5 (SWIFT-PRIME)f | 95 | 71:24 | 54 | 65.0 (12.5) | 9 (7–10) | 17 (13–20) | 90 | 71:19 | 54 | 65.0 (12.5) | 9 (7–10) | 17 (13–20) | 6–7, 8–10 |
| Spiotta13 | 149 | 72 | 66.1 (15.1) | 8 (3–10)g | 16.2 (6.7)h | 1–6, 7–10 | |||||||
| Kim24 | 171 | 88 | 72 (63.5–78)i | 7 (6–8) | 13 (10–16) | MRI-ASPECTS (4–6, 7–10) | |||||||
Abbreviations: A, anterior circulation; A-P, anterior and posterior circulation (number of posterior circulation); ASPECTS, Alberta Stroke Program Early CT Scale; CT, computed tomography; iA, intra-arterial thrombolysis; ICA, internal carotid artery; iv tPA; intravenous tissue plasminogen activator infusion; LAO, large artery occlusion; MCA. Middle cerebral artery; N, No; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; NR, not reported; SD, standard deviation; TICI, Thrombolysis in Cerebral Infarction; TIMI, Thrombolysis in Myocardial Infarction; Y, yes
a: Among 51 patients who were enrolled in this study, follow up mRS were available in 48 patients. The data of ‘characteristics of patients’ was collected from 51 patients.
b: Odds ratio was adjusted.
c: The information of characteristics of subjects were extracted from the per protocol population (165 and 150). Subjects which used in meta-analysis are provided in ancillary analysis including protocol violators and excluding follow-up loss.
d: Among 103 patients who were enrolled in this study, number of successful recanalization and ICA occlusion were available in 102 patients.
e: In DEFUSE 2 trial, Merci device, Penumbra system, and intra-arterial tPA were used to most of patients and only 6 stentrievers were used. Combinations of more than one endovascular therapy were used in 45%.
f. The information of characteristics of subjects were extracted from the per protocol population (98 and 98)
g. median (range)
h. mean (standard deviation)
i. median and interquartile range (IQR)
j. 9 protocol violators (0~5) included.